The 2019 American Society of Clinical Oncology’s meeting might be in the books, but the impact of some of the data released at the conference are certain to have implications for cancer patients for years to come.
Myriad Genetics presented data from several studies at ASCO that will no doubt have a long-lasting impact on cancer detection and treatment. The Salt Lake City, UT-based company spoke with MD+DI during ASCO about results from both colorectal cancer and breast cancer studies.
Some of the most talked-about results came from the Phase III POLO Study, which looked at how well the BRACAnalysis CDx identified patients with metastatic pancreatic cancer, who benefitted from treatment of Lynparza (olaparib). AstraZeneca and Merck are commercially developing Lynparza. It is not currently approved by FDA for gBRCAm pancreatic cancer.
“Because every patient in the study was tested and shown to be BRACAnalysis CDx positive, it reinforces that every patient with pancreatic cancer needs to undergo genetic testing to establish whether they are candidates for Lynparza, a PARP inhibitor and are likely to benefit from the drug,” Johnathan Lancaster, MD, PhD, CMO, Myriad Genetics, told MD+DI.
Specifically, the POLO study demonstrated that patients with a germline mutation, and whose disease had not progressed on first-line platinum-based chemotherapy, had a clinically-meaningful and statistically-significant improvement in progression-free survival (PFS) of 7.4 months when treated with Lynparza compared to 3.8 months for placebo (HR 0.53; p=0.004)…